Recently, Liu suggested that valproic acid (VPA) could reverse TGF-B-induced sorafenib resistance in HCC cells by reducing the Jagged2-mediated Notch1 signaling pathway and altering the EMT phenotype (133). Here, NOTCH1 is linked to hepatocellular carcinoma.